Literature DB >> 2019419

FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a.

R Inagi1, T Miyata, K Maeda, S Sugiyama, A Miyama, I Nakashima.   

Abstract

We examined the inhibitory effect of FUT-175 on the C3/C5 convertase activity of the cobra venom factor-derived enzyme CVF,Bb by measuring C5b6-mediated reactive lysis of unsensitized guinea pig erythrocytes and by measuring directly the released fragments C3-des-Arg and C5a-des-Arg. In this study, we showed that the concentration of 4.5 X 10(-6) M of FUT-175 caused 50% inhibition of C5 convertase activity of CVF,Bb in reactive hemolysis assays, and that 4.0 X 10(-6) M FUT-175 caused 50% inhibition of the production of C3a and C5a generated by the C3/C5 convertase activity of CVF,Bb.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019419     DOI: 10.1016/0165-2478(91)90243-4

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  10 in total

Review 1.  Development of complement therapeutics for inhibition of immune-mediated red cell destruction.

Authors:  Karina Yazdanbakhsh
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

2.  Survival of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 258 in Human Blood.

Authors:  Frank R DeLeo; Scott D Kobayashi; Adeline R Porter; Brett Freedman; David W Dorward; Liang Chen; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  Near completely humanized liver in mice shows human-type metabolic responses to drugs.

Authors:  Chise Tateno; Yasumi Yoshizane; Naomi Saito; Miho Kataoka; Rie Utoh; Chihiro Yamasaki; Asato Tachibana; Yoshinori Soeno; Kinji Asahina; Hiroshi Hino; Toshimasa Asahara; Tsuyoshi Yokoi; Toshinori Furukawa; Katsutoshi Yoshizato
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 4.  New advances in measurement of complement activation: lessons of systemic lupus erythematosus.

Authors:  Chau-Ching Liu; Susan Manzi; Natalya Danchenko; Joseph M Ahearn
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

5.  Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Eveline Y Wu; Elizabeth A McInnis; Sonia Boyer-Suavet; Carmen E Mendoza; Lydia T Aybar; Kristin B Kennedy; Caroline J Poulton; Candace D Henderson; Yichun Hu; Susan L Hogan; Peiqi Hu; Hong Xiao; Patrick H Nachman; J Charles Jennette; Ronald J Falk; Donna O Bunch
Journal:  Arthritis Rheumatol       Date:  2019-10-08       Impact factor: 10.995

6.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12

Review 7.  Neuronal death in Alzheimer's disease and therapeutic opportunities.

Authors:  Rossen Donev; Martin Kolev; Bruno Millet; Johannes Thome
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

8.  The Vi capsular polysaccharide enables Salmonella enterica serovar typhi to evade microbe-guided neutrophil chemotaxis.

Authors:  Tamding Wangdi; Cheng-Yuk Lee; Alanna M Spees; Chenzhou Yu; Dawn D Kingsbury; Sebastian E Winter; Christine J Hastey; R Paul Wilson; Volkmar Heinrich; Andreas J Bäumler
Journal:  PLoS Pathog       Date:  2014-08-07       Impact factor: 6.823

Review 9.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

10.  Ecotin, a microbial inhibitor of serine proteases, blocks multiple complement dependent and independent microbicidal activities of human serum.

Authors:  Zoltán Attila Nagy; Dávid Szakács; Eszter Boros; Dávid Héja; Eszter Vígh; Noémi Sándor; Mihály Józsi; Gábor Oroszlán; József Dobó; Péter Gál; Gábor Pál
Journal:  PLoS Pathog       Date:  2019-12-20       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.